Facebook Twitter LinkedIn Google Plus RSS

Cancer Genetics closes IPO

By ,

Rutherford-based Cancer Genetics Inc., a diagnostics company focused on developing genomic-based oncology tests and services, today announced it has closed its initial public offering of 690,000 shares of common stock at a price to the public of $10 per share.

Total gross proceeds from the offering were $6.9 million before deducting underwriting discounts and commissions and other offering expenses payable by Cancer Genetics, according to the company.

Also Popular on NJBIZ

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy